Bristol Drug Patent Portfolio
Bristol owns 8 orange book drugs protected by 52 US patents with Krazati having the least patent protection, holding only 1 patent. And Pomalyst with maximum patent protection, holding 27 patents. Given below is the list of Bristol's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11680050 | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof | 30 Sep, 2038 | Active |
| US10689377 | KRas G12C inhibitors | 17 May, 2037 | Active |
| US11452725 | Chiral diaryl macrocycles and uses thereof | 24 Jul, 2036 | Active |
| US10294242 | Diaryl macrocycle polymorph | 05 Jul, 2036 | Active |
| US12187739 | Diaryl macrocycle polymorph | 05 Jul, 2036 | Active |
| US9714258 | Diaryl macrocycles as modulators of protein kinases | 23 Jan, 2035 | Active |
| US9181200 | Pyrimidinedione compounds | 19 Jun, 2034 | Active |
| US9585883 | Pyrimidinedione compounds | 19 Jun, 2034 | Active |
| USRE50050 | Pyrimidinedione compounds | 19 Jun, 2034 | Active |
| US10000480 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | 07 Nov, 2033 | Active |
| US11021475 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | 07 Nov, 2033 | Active |
| USRE47929 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | 07 Nov, 2033 | Active |
| US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | 06 Oct, 2032 | Active |
| US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 21 Dec, 2031 | Active |
| US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 21 Jun, 2031 | Active |
| US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 19 Nov, 2030 | Active |
| US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 19 Nov, 2030 | Active |
| US10239846 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | 15 Nov, 2030 | Active |
| US8846628 | Oral formulations of cytidine analogs and methods of use thereof | 03 Jun, 2030 | Active |
| US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 19 May, 2030 | Active |
| US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | 19 May, 2030 | Active |
| US8148374 | Modulators of pharmacokinetic properties of therapeutics | 03 Sep, 2029 | Active |
| US11571436 | Oral formulations of cytidine analogs and methods of use thereof | 14 May, 2029 | Active |
| US12053482 | Oral formulations of cytidine analogs and methods of use thereof | 14 May, 2029 | Active |
| US8481573 | Modulators of sphingosine phosphate receptors | 14 May, 2029 | Active |
| US8796318 | Modulators of sphingosine phosphate receptors | 14 May, 2029 | Active |
| US9382217 | Modulators of sphingosine phosphate receptors | 14 May, 2029 | Active |
| US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 17 Dec, 2025 | Active |
| US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 17 Jun, 2025 | Active |
| US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 15 Nov, 2023 | Expired |
| US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 15 Nov, 2023 | Expired |
| US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 15 May, 2023 | Expired |
| US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | 15 May, 2023 | Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug | 23 Oct, 2020 | Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor | 21 Jun, 2019 | Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor | 21 Dec, 2018 | Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives | 20 Dec, 2017 | Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives | 20 Jun, 2017 | Expired |
| US6316471 | Isoindolines, method of use, and pharmaceutical compositions | 10 Aug, 2016 | Expired |
| US8158653 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline | 10 Aug, 2016 | Expired |
| US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | 24 Jul, 2016 | Expired |
| US5653517 | Process and system for determination of friction/slip characteristics of road vehicle tires | 24 Jul, 2016 | Expired |
| US6476052 | Isoindolines, method of use, and pharmaceutical compositions | 24 Jul, 2016 | Expired |
Latest Legal Activities on Bristol's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bristol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jul, 2024 | US8315886 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 24 Jun, 2024 | US9585883 |
|
Email Notification
Critical
| 21 Mar, 2024 | US10689377 |
| Mail O.P. Petition Decision | 21 Mar, 2024 | US10689377 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 19 Mar, 2024 | US10689377 |
| Record Petition Decision of Granted to Make Entity Status large | 18 Mar, 2024 | US10689377 |
| O.P. Petition Decision | 16 Mar, 2024 | US10689377 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9181200 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9585883 |
| Initial letter Re: PTE Application to regulating agency | 16 Feb, 2024 | US9714258 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 15 Feb, 2024 | US9714258 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Feb, 2024 | US8204763 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 Jan, 2024 | US9714258 |
|
Email Notification
Critical
| 22 Jan, 2024 | US9714258 |
| Requirement for information sent under 37 CFR 1.750 | 16 Jan, 2024 | US9714258 |
Bristol's Drug Patent Litigations
Bristol's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2015, against patent number US5635517. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8846628 | February, 2023 |
Terminated-Settled
(05 Jan, 2024)
| CELGENE CORPORATION et al. | Apotex Inc. et al. |
| US6045501 | April, 2015 |
Final Written Decision
(26 Oct, 2016)
| Celgene Corporation | Coalition For Affordable Drugs VI LLC |
| US6315720 | April, 2015 |
FWD Entered
(26 Oct, 2016)
| Celgene Corporation | Coalition for Affordable Drugs VI LLC |
| US5635517 | May, 2015 |
Terminated-Denied
(16 Nov, 2015)
| Celgene Corporation | Coalition for Affordable Drugs VI LLC |
Bristol Drug Patents' Oppositions Filed in EPO
Bristol drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 30, 2010, by Synthon B.V.. This opposition was filed on patent number EP03728969A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP20201105A | Apr, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP20201105A | Apr, 2023 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP20201105A | Mar, 2023 | Synthon BV | Granted and Under Opposition |
| EP20201105A | Mar, 2023 | SANDOZ AG | Granted and Under Opposition |
| EP20201105A | Mar, 2023 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP19213148A | May, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP19213148A | May, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP19213148A | May, 2022 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
| EP19213148A | May, 2022 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
| EP19213148A | May, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP19213148A | Apr, 2022 | Lotus Pharmaceutical Co., Ltd. | Granted and Under Opposition |
| EP16180589A | Oct, 2020 | Cooke, Richard | Granted and Under Opposition |
| EP16180589A | Oct, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP13182721A | Sep, 2020 | SANDOZ AG | Granted and Under Opposition |
| EP13182721A | Sep, 2020 | Hoffmann Eitle | Granted and Under Opposition |
| EP13182721A | Sep, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP13182721A | Aug, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP16180589A | Jan, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP18160247A | Jan, 2020 | Hoffmann Eitle | Granted and Under Opposition |
| EP18160247A | Jan, 2020 | Generics (UK) Ltd | Granted and Under Opposition |
| EP18160247A | Jan, 2020 | HGF Limited | Granted and Under Opposition |
| EP18160247A | Dec, 2019 | Pruß, Timo | Granted and Under Opposition |
| EP09746975A | Aug, 2019 | Generics (UK) Ltd | Granted and Under Opposition |
| EP09746975A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP15199521A | Aug, 2019 | Bachelin, Martin, Dr. | Revoked |
| EP15199521A | Aug, 2019 | Hamm&Wittkopp Patentanwälte PartmbB | Revoked |
| EP15199521A | Aug, 2019 | Generics [UK] Ltd | Revoked |
| EP15199526A | Aug, 2019 | Generics [UK] Ltd | Revoked |
| EP15199540A | Aug, 2019 | Generics (UK) Ltd | Revoked |
| EP15199521A | Jul, 2019 | Pruß, Timo | Revoked |
| EP15199521A | Jul, 2019 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Revoked |
| EP10830880A | Dec, 2018 | Generics [UK] Ltd | Granted and Under Opposition |
| EP10720107A | Oct, 2017 | Hoffmann Eitle | Revoked |
| EP10720107A | Oct, 2017 | STADA Arzneimittel AG | Revoked |
| EP10720107A | Oct, 2017 | HGF Limited | Revoked |
| EP10720107A | Oct, 2017 | Generics [UK] Ltd | Revoked |
| EP10720107A | Oct, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP12167590A | May, 2017 | Cooke, Richard | Revoked |
| EP12167591A | May, 2017 | Cooke, Richard | Revoked |
| EP12167591A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP12167590A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP12167589A | May, 2017 | Cooke, Richard | Granted and Under Opposition |
| EP12167589A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP12167596A | Apr, 2017 | Cooke, Richard | Revoked |
| EP12167596A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP09739981A | Jun, 2016 | Cooke, Richard | Revoked |
| EP09739981A | Jun, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP10703766A | Apr, 2016 | Cooke, Richard | Revoked |
| EP10703766A | Apr, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP07836007A | Mar, 2016 | Trösch, Dominique | Granted and Under Opposition |
| EP07836007A | Mar, 2016 | Georg Kalhammer/Stephan Teipel | Granted and Under Opposition |
| EP07836007A | Mar, 2016 | Teva Pharmaceutical Industries LTD. | Granted and Under Opposition |
| EP09008756A | Jul, 2015 | Accord Healthcare Ltd | Revoked |
| EP09008756A | Jul, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP09008756A | Jul, 2015 | Hexal AG | Revoked |
| EP09008756A | Jul, 2015 | Intellectual Property Services | Revoked |
| EP09008756A | Jul, 2015 | Synthon B.V. | Revoked |
| EP09008756A | Jul, 2015 | Actavis Group PTC EHF | Revoked |
| EP04783095A | Aug, 2012 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP04783095A | Aug, 2012 | Generics [UK] Limited | Revoked |
| EP03728969A | Dec, 2010 | STRAWMAN LIMITED | Revoked |
| EP03728969A | Nov, 2010 | Synthon B.V. | Revoked |
Bristol's Family Patents
Bristol drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 18.9% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Bristol Drug List
Given below is the complete list of Bristol's drugs and the patents protecting them.
1. Augtyro
Augtyro is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11452725 | Chiral diaryl macrocycles and uses thereof |
24 Jul, 2036
(11 years from now)
| Active |
| US10294242 | Diaryl macrocycle polymorph |
05 Jul, 2036
(11 years from now)
| Active |
| US12187739 | Diaryl macrocycle polymorph |
05 Jul, 2036
(11 years from now)
| Active |
| US9714258 | Diaryl macrocycles as modulators of protein kinases |
23 Jan, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Augtyro's drug page
2. Camzyos
Camzyos is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9181200 | Pyrimidinedione compounds |
19 Jun, 2034
(9 years from now)
| Active |
| US9585883 | Pyrimidinedione compounds |
19 Jun, 2034
(9 years from now)
| Active |
| USRE50050 | Pyrimidinedione compounds |
19 Jun, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Camzyos's drug page
3. Evotaz
Evotaz is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(7 years from now)
| Active |
| US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
| US6087383
(Pediatric)
| Bisulfate salt of HIV protease inhibitor |
21 Jun, 2019
(5 years ago)
| Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor |
21 Dec, 2018
(6 years ago)
| Expired |
| US5849911
(Pediatric)
| Antivirally active heterocyclic azahexane derivatives |
20 Dec, 2017
(7 years ago)
| Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives |
20 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evotaz's drug page
4. Krazati
Krazati is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10689377 | KRas G12C inhibitors |
17 May, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Krazati's drug page
5. Onureg
Onureg is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846628 | Oral formulations of cytidine analogs and methods of use thereof |
03 Jun, 2030
(5 years from now)
| Active |
| US11571436 | Oral formulations of cytidine analogs and methods of use thereof |
14 May, 2029
(4 years from now)
| Active |
| US12053482 | Oral formulations of cytidine analogs and methods of use thereof |
14 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onureg's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Pomalyst
Pomalyst is protected by 27 patents, out of which 19 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8828427
(Pediatric)
| Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
21 Dec, 2031
(6 years from now)
| Active |
| US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
21 Jun, 2031
(6 years from now)
| Active |
| US10555939
(Pediatric)
| Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
19 Nov, 2030
(5 years from now)
| Active |
| US9993467
(Pediatric)
| Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
19 Nov, 2030
(5 years from now)
| Active |
| US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
19 May, 2030
(5 years from now)
| Active |
| US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
19 May, 2030
(5 years from now)
| Active |
| US8198262
(Pediatric)
| Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
17 Dec, 2025
(7 months from now)
| Active |
| US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
17 Jun, 2025
(a month from now)
| Active |
| US8673939
(Pediatric)
| Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
15 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8735428
(Pediatric)
| Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
15 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
15 May, 2023
(1 year, 11 months ago)
| Expired |
| US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
15 May, 2023
(1 year, 11 months ago)
| Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
23 Oct, 2020
(4 years ago)
| Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6316471 | Isoindolines, method of use, and pharmaceutical compositions |
10 Aug, 2016
(8 years ago)
| Expired |
| US8158653 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
10 Aug, 2016
(8 years ago)
| Expired |
| US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
24 Jul, 2016
(8 years ago)
| Expired |
| US5653517 | Process and system for determination of friction/slip characteristics of road vehicle tires |
24 Jul, 2016
(8 years ago)
| Expired |
| US6476052 | Isoindolines, method of use, and pharmaceutical compositions |
24 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pomalyst's drug page
7. Sotyktu
Sotyktu is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10000480 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
07 Nov, 2033
(8 years from now)
| Active |
| US11021475 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
07 Nov, 2033
(8 years from now)
| Active |
| USRE47929 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
07 Nov, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sotyktu's drug page
8. Zeposia
Zeposia is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11680050 | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
30 Sep, 2038
(13 years from now)
| Active |
| US10239846 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
15 Nov, 2030
(5 years from now)
| Active |
| US8481573 | Modulators of sphingosine phosphate receptors |
14 May, 2029
(4 years from now)
| Active |
| US8796318 | Modulators of sphingosine phosphate receptors |
14 May, 2029
(4 years from now)
| Active |
| US9382217 | Modulators of sphingosine phosphate receptors |
14 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zeposia's drug page